Median duration of recurrence-free survival was 61.1 months with nivolumab and ...
Complete response rate was 37 percent, and post-hoc end point of ...
80 percent of adult patients with stage III/IV resectable melanoma remained ...
Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ ...